RE:RE:RE:Something big is likely in the works I don't know if you remember, but Marsolais said in a recent CC that they have many development projects submitted to them by academic research people here in Montreal and that they are considering some for the future. It's the new model in biopharma.
To further develop the SORT1+ platform they don't need a huge team. It's not rocket science, it's pretty basic chemistry by today's standards. Then animal testing is not complicated either. Add to that the fact that they use Beliveau's lab instruments in some cases, and some expertise from his lab. They just hired a new PhD researcher in medecinal chemistry. I think it's enough to do the work of pairing TH19P01 with other cytotoxic drugs.
SPCEO1 wrote: I am not sure what to exactly make of the hiring efforts. Hiring a Chief of Staff would seem to indicate that a friendly takeover is not in the offing and Paul is planning on handling things himself. And the lack of extensive hiring on the research front seems to indicate TH thinks most new reseach will be done by a partner as I can't believe the research resources they currently have are suffcient to take on the many different avenues they could travel in the next few years on cancer. Do you think the lack of scientific hires is telling us they are looking at a partnering strategy, for the most part, to take cancer forward?
jfm1330 wrote: Never sure of anything, but this makes sense. Add to that a lot of hiring for important positions.
SPCEO1 wrote: Evidence:
1.) They managed to get the retired Pfizer CMO as a scientific consutant
2.) They liked their IR officer but she left because a family situation would not allow her to travel - so they needed someone in that role who could travel and explain what is going to be announced.
3.) They have gone totally silent yet still have meetings scheduled with large shareholders later this month.
4.) They pulled the corporate presentation and have not yet replaced it. It would be pretty easy to update if there was not something significant going on that would really lead to material changes.
5.) They gave larger options grants and gave them earlier than normal.
My best guess is whatever is coming down the pike will be viewed as a positive development. The chances of a big fundraising occurring on the back of any such good news is high, unless the good news is partnership agreements that bring upfront cash along with them.
There could be a series of pieces of good news - China cancer partnership, other cancer partnerships, NASH partnership, acquisition of other drugs, selling Trogarzo rights to someone else to concentrate on Egrifta and cancer, etc.
There could also be a friendly acquisition of THTX in play and that is why things have gone silent and big options grants, etc.
While the market is tired of the wait for news, there is meaningful evidence that something signifcant and good is being worked on behind the scenes.